The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for IsoAid sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
IsoAid LLC (IsoAid) is a medical device company that offers brachytherapy seeds and related products. The company offers radioactive seeds which include advantage I-125, and advantage Pd-103. Its prostate brachytherapy products comprise pre-loaded seeds, loose seeds, stranded seeds and mick seeds. IsoAid also offers treatment for beating prostate cancer. Its eye plaque brachytherapy’s products include cdvantage I-125 seeds. IsoAid also offers support of community outreach programs, reimbursement consultation and patient education services. The company markets its products through distributors in the US, Canada, and others. IsoAid is headquartered in Port Richey, Florida, the US.
The key metrics of IsoAid related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As IsoAid is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as IsoAid.
For a detailed understanding of the performance of IsoAid, buy the report here.